Загрузка...
Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1...
Сохранить в:
| Опубликовано в: : | Clin Cosmet Investig Dermatol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628099/ https://ncbi.nlm.nih.gov/pubmed/31372022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CCID.S211938 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|